Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer
Schöffski, Patrick × Thate, B Beutel, G Bolte, O Otto, D Hofmann, M Ganser, A Jenner, A Cheverton, P Wanders, J Oguma, T Atsumi, R Satomi, M #
Kluwer Academic Publishers
Annals of Oncology vol:15 issue:4 pages:671-679
Background: TZT-1027 is a synthetic dolastatin 10 analog with antineoplastic properties in various cell lines and tumor xenografts. The purpose of this phase I study was to evaluate the safety and toxicity, maximum tolerated dose, pharmacokinetics and pharmacodynamics, clinical and metabolic antitumor activity of TZT-1027 when given as a 1-h intravenous infusion every 3 weeks in patients with refractory solid tumors.